Aurora, CO, August 26, 2004. GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of five management team members including key hires at the director and department head level. “We are pleased that GlobeImmune has continued to attract the high level of talent represented by these experienced managers,” said Timothy C. Rodell, M.D., GlobeImmune’s Chief Executive Officer. “The addition of these members to our team increases the resources and expertise we can bring to bear on successful development and commercialization of our immunotherapies.”
Ed Venkat, Ph.D., has accepted the position of Director of Process Development. Dr. Venkat has over 20 years experience in process development, scale up, and yeast fermentation, including nearly 20 years of manufacturing engineering experience at Merck where he was most recently Senior Research Fellow.
Aurelia Haller, Ph.D., joined the Company as Virology Program Leader. She has over 15 years experience in molecular virology and molecular genetics including, most recently, Group Leader of the parainfluenza viral vector program at Aviron (MedImmune).
Carol Walker has been named Director, Quality Control. Ms. Walker has over 15 years experience in parenteral pharmaceutical and biopharmaceutical quality assurance and control including, most recently, Section Head and QA Director of Wyeth Vaccines, and QC Director for Baxter Hyland Immuno.
Aline Oliver joined the Company as Associate Director of Quality Assurance. Ms. Oliver has over 14 years experience in biologic, biotechnology, and device quality including authoring Chemistry, Manufacturing and Controls sections of regulatory filings, and establishing GMP compliance systems at companies such as Sulzer Biologics, Cortech, and Synergen.
Grant Wiemers has been hired as Controller and Director of Finance and brings over 12 years experience managing diverse functions in both finance and operations in early-stage environments. He has been a key member of teams which successfully raised capital for technology-based start-up companies and has managed assets in excess of $30M.
About GlobeImmune
GlobeImmune, Inc. is an early-stage biopharmaceutical company pioneering the development of potent, targeted molecular immunotherapies for the treatment of cancer and infectious diseases. The Company’s first products for the treatment of cancers of the lung and gastrointestinal tract are currently in Phase 1 clinical trials. For additional information, please visit the Company’s website at https://globeimmune.com/. GlobeImmune is headquartered at the Fitzsimons BioScience Park in Aurora, Colorado.
Contact:
Timothy C. Rodell, M.D, CEO
GlobeImmune, Inc.
720-859-4070